Consensus prevention of deep venous thrombosis

In a consensus meeting on the prophylaxis of deep venous thrombosis guidelines were given - especially for the Dutch situation - concerning the use of mechanical measures (elastic stockings, intermittent pneumatic compression) and of antithrombotic medication (low doses of heparin, coumarin derivatives, dextrans) in various groups of surgical and non-surgical patients.     

急性肠系膜静脉血栓形成的介入治疗

目的探讨介入治疗急性肠系膜静脉血栓形成(AMVT)的方法及疗效。方法对15例经影像学确诊的AMVT患者进行了介入治疗,其中经肠系膜上动脉途径溶栓治疗8例,经皮经肝穿刺门静脉途径机械性取栓5例,经颈静脉经肝穿刺门静脉途径机械性取栓2例。结果15例患者均获成功,介入治疗后腹痛消失,血管造影可见肠系膜上静脉内血流通畅。本组均获随访,随访时间为10～22个月,均未复发。结论对于早期AMVT病例,介入治疗是一种较好的方法。     

急性肠系膜静脉血栓形成的介入治疗

目的探讨介入治疗急性肠系膜静脉血栓形成（AMVT）的方法及疗效。方法对15例经影像学确诊的AMVT患者进行了介入治疗，其中经肠系膜上动脉途径溶栓治疗8例，经皮经肝穿刺门静脉途径机械性取栓5例，经颈静脉经肝穿刺门静脉途径机械性取栓2例。结果15例患者均获成功，介入治疗后腹痛消失，血管造影可见肠系膜上静脉内血流通畅。本组均获随访，随访时间为10～22个月，均未复发。结论对于早期AMVT病例，介入治疗是一种较好的方法。     

速碧林对孕产妇围产期深静脉血栓发生率的影响

目的分析孕产妇围产期应用速碧林对深静脉血栓发生率的影响。方法选取2016年4月—2017年4月接受分娩手术的产妇162例,按照随机分配原则均分为对照组和研究组,各81例。两组产后均给予常规抗血栓治疗,研究组在此基础上给予速碧林治疗。观察两组产妇分娩后新生儿体重和胎盘平均重量,产妇机体凝血功能状况以及用药后不良反应发生情况。计量资料比较采用t检验,计数资料比较采用χ~2检验,P0.05为差异有统计学意义。结果研究组新生儿胎龄、体重、及胎盘重量[(38.04±3.87)w、(3.76±0.84)kg、(436.91±61.52)g]高于对照组[(36.86±3.73)w、(2.48±0.77)kg、(345.6±55.42)g](均P0.05),研究组新生儿窒息发生率(1.23%)低于对照组(11.11%);研究组治疗后Fbg和D-二聚体含量[(4.1±1.9)mg/L、(2.3±0.8)g/L]与对照组[(5.2±4.1)mg/L、(1.9±0.8)g/L]比较,差异有统计学意义(均P0.05);研究组治疗后不良反应发生率低于对照组(P0.05)。结论速碧林应用在孕产妇围术期可有效降低深静脉血栓发生率,取得理想的抗血栓效果。     

骨科手术后下肢深静脉血栓形成的彩色多普勒超声诊断

目的讨论彩色多普勒超声对骨科手术后患者并发下肢深静脉血栓形成的应用价值。方法对1204例骨科手术患者的下肢深静脉进行彩色多普勒超声检查。结果彩色多普勒检查的1204例骨科手术后患者中,并发深静脉衄栓占53例。结论彩色多普勒超声检查能及时确定下肢深静脉血栓部位、范围及阻塞程度,有利于临床早诊断、早治疗、早预防。     

Use of deep venous thrombosis prophylaxis by family physicians.

BACKGROUND: Accumulated data indicate that the administration of low-dose subcutaneous heparin reduces the incidence of deep venous thrombosis in high-risk surgical and medical patients. Because deep venous thrombosis predisposes to pulmonary embolism, it is generally accepted that reducing deep venous thrombosis will reduce pulmonary embolism, the most common preventable cause of death in hospitalized patients. There are few data, however, regarding physicians' use of heparin for deep venous thrombosis prophylaxis in medical patients. METHODS: We reviewed charts of medical patients aged 50 years and older who were admitted to family practice services in a community teaching hospital and excluded patients who were not candidates for heparin prophylaxis. RESULTS: Eighty (65 percent) of 123 patients received heparin for deep venous thrombosis prophylaxis. Patients admitted to a residency teaching service were more likely to receive heparin for deep venous thrombosis prophylaxis than were patients admitted to nonteaching services (odds ratio 3.37, 95 percent confidence interval 1.26-9.21, P = 0.012). An association between the patient's number of risk factors for deep venous thrombosis and likelihood of receiving deep venous thrombosis prophylaxis approached statistical significance (P = 0.078). CONCLUSIONS: In our institution, heparin for deep venous thrombosis prophylaxis is frequently but not uniformly prescribed for appropriately selected family practice inpatients. No similar data for nonsurgical patients were found for comparison.